South Korea-based artificial intelligence (AI) healthcare company Deep Bio is working with CancerX on an initiative to change the landscape of cancer diagnosis and treatment.
The CancerX initiative was launched earlier this year, as part of the White House Cancer Moonshot program launched by US president Joe Biden and the first lady Jill Biden. The initiative aims to prevent more than 4 million cancer deaths by 2047 and accelerate progress in cancer research, diagnosis, and treatment.
CancerX brings together like-minded organizations and experts to work on new solutions to excel cancer research. This latest partnership will see Deep Bio bring its latest In Vitro Diagnostic (IVD) Software as a Medical Device (SaMDs) powered by deep learning algorithms to the initiative.
Sun Woo Kim, CEO of Deep Bio said: “Cancer remains one of the most pressing global health challenges, and collaborative efforts are vital in combating this disease. Our participation in CancerX is a testament to our dedication to improving the lives of cancer patients and healthcare professionals.”
He added: “Through the utilization of artificial intelligence, we aim to make cancer diagnostics more accurate, efficient, and accessible. Partnering with CancerX will amplify our impact and bring us closer to realizing this vision.”
Deep Bio’s involvement in the CancerX initiative reiterates its commit to providing cancer solutions. In 2022 Deep Bio deployed AI support for prostate cancer diagnosis at five Korean hospitals.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
Your download email will arrive shortly
We are confident about the
quality of our Company Profiles. However, we want you to make the most
decision for your business, so we offer a free sample that you can download by
submitting the below form
In the same year the company also signed a partnership agreement with Visiopharm, an AI powered image analysis and tissue mining for research and diagnostics company. The agreement provided pathologists access to the latest AI powered prostate cancer solution.